SEARCH

SEARCH BY CITATION

References

  • BACH, A.W.J., LAN, N.C., JOHNSON, D.L, ABELL, C.W., BEMBEREK, M.E., KWAN, S.W., SEEBERG, P.H. & SHIH, J. (1988). cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Nat. Acad. Sci. U.S.A., 85, 49344938.
  • BIRKMAYER, W., RIEDERER, P., AMBROZI, L. & YOUDIM, M.B.H. (1977). Implications of combined treatment with Madopar and 1-deprenyl in Parkinson's disease. Lancet, 2, 439443.
  • BIRKMAYER, W., RIEDERER, P., YOUDIM, M.B.H. & LINAUER, W. (1975). The potentiation of anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J. Neural Transm., 36, 303326.
  • COLLINS, G.G.S., SANDLER M., WILLIAMS, E.D. & YOUDIM, M.B.H. (1970). Multiple forms of human brain mitochondrial monoamine oxidase. Nature, 225, 817820.
  • DELLA CORTE, L. & TIPTON, K.F. (1980). The turnover of the A and B-forms of monoamine oxidase in rat liver. Biochem. Pharmacol., 29, 811815.
  • FINBERG, J.P.M. & YOUDIM, M.B.H. (1985). Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors of types A and B in the cat. Br. J. Pharmacol., 85, 541546.
  • FINBERG, J.P.M., LAMENSDORF, I., COMMISSIONG, J.W. & YOUDIM, M.B.H. (1996). Pharmacology and neuroprotective properties of rasagiline. J. Neural. Transm., 48, Suppl. 95103.
  • FINBERG, J.P.M., LAMENSDORF, I., WEINSTOCK, M., SCHWARTZ, M. & YOUDIM, M.B.H. (1999). Pharmacology of rasagiline (N-propargyl-IR-aminoindan). Adv. Neurol., 80, 495501.
  • FINBERG, J.P.M., TAKESHIMA, T., JOHNSTON, J.M. & COMMISSIONG, J.W. (1998). Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport, 9, 703707.
  • FINBERG, J.P.M., TENNE, M. & YOUDIM, M.B.H. (1981). Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol., 73, 6574.
  • FOWLER, J.S., VOLKOW, N.D., LOGAN, J., WANG, G.J., MACGREGOR, R.R., SCHYLER, D., WOLF, A.D., PAPPAS, M., ALEXOFF, D. & SHEA, C. (1994). Slow recovery of human brain MAO B after deprenyl (selegiline) withdrawal. Synapse, 18, 8693.
  • GOTZ, M.E., BREITHAUPT, W., SAUTTER, J., KUPSCH, A., SCHWARZ, J., OERTEL, W.H., YOUDIM, M.B.H., RIEDERER, P. & GERLACH, R.Y. (1998). Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm., 52 Suppl. 271278.
  • GREEN, A.R., TORDOFF, A., MITCHEL, B. & YOUDIM, M.B.H. (1977). Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for degree of inhibition of enzyme necessary for increased function and activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol., 60, 343349.
  • HUANG, W., CHEN, Y., SHOHAMI, E. & WEINSTOCK, M. (1999). Neuroprotective effect of rasagiline, a selective monoamine oxidase B inhibitor, against head injury in the mouse. Eur. J. Pharmacol., 366, 127135.
  • KALIR, A., SABBAGH, A. & YOUDIM, M.B.H. (1981). Selective ‘suicide’ acetylenic and reversible inhibitors of monoamine oxidase A and B. Br. J. Pharmacol., 73, 5564.
  • KEARNEY, F.B., SALACH, J.I., WALKER, W.H., SENG, R.L., KENNEY, W., ZESZOLEK, E. & SINGERT. P.(1971). The covalently bound flavin of hepatic monoamine oxidase I. Isolation and sequence of a flavin peptide and evidence for binding to the 8∞-position. Eur. J. Biochem., 24, 321327.
  • KNOLL, J. & MAGYAR, K. (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol., 5, 393408.
  • LEES, A., SHOW, K.M., KAHOUT, L.J., STERN, G., ELSWORTH, J.D., SANDLER, M. & YOUDIM, M.B.H. (1977). Deprenyl in Parkinson's Disease. Lancet, (ii), 791795.
  • LOWRY, O.G., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with Folin phenol reagent. J. Biol. Chem., 193, 265275.
  • MAITRE, L., DELINI-STULA, A. & WALDMEIER, P.C. (1976). Relation between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors.Ciba Foundation Symposium No. 39 pp. 247267, Amsterdam: Elsevier.
  • MAYCOCK, A.L., ABELES, R.H., SALACH, J. & SINGER, T.P. (1976). The action of acetylenic inhibitors on mitochondrial monoamine oxidase: Structure of the flavin site in the inhibited enzyme. Ciba Foundation Symposium No. 39. pp. 3349, Amsterdam: Elsevier.
  • NEFF, N.H. & GORDIS, C. (1972). Neuronal monoamine oxidase: Specific enzyme types and their rates of formation. Adv. Biochem. Psychopharmacol., 5, 307324.
  • O'CARROLL, A.M., FOWLER, C.J., PHILLIP, J.P., TOBIA, I. & TIPTON, K.F. (1983). The deamination of dopamine by human brain monoamine oxidase. Specificity for the two forms in seven brain regions. Naunyn Schmiedebergs Arch. Pharmacol., 322, 198207.
  • PARKINSON STUDY GROUP (DATATOP). (1989). Selegiline and Parkinson's disease. N. Engl. J. Med., 321, 13641371.
  • REYNOLDS, G.P., RIEDERER, P., SANDLER, N.R., JELLINGER, K. & SEEMALI, D. (1978). Amphetamine and 2-phenylethylamine in post mortem Parkinson brains after 1-deprenyl administration. J. Neural. Transm., 43, 271278.
  • RIEDERER, P. & RINNE, U.K. (1992). Selegiline in Parkinson's Disease: An update. Mov. Disords., 8(Suppl. 1), 51544.
  • SABBAGH, A. & YOUDIM, M.B.H. (1978). Selective inhibition of monoamine oxidase type B by propargyl-containing drugs. Israel J. Med. Sci., 14, 1097.
  • SALACH, J., DETMER, K. & YOUDIM, M.B.H. (1978). The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. Mol. Pharmacol., 16, 234241.
  • SALACH, J., SINGER, T.P., YAUNOBU, K.T., MONAMURA, N. & YOUDIM, M.B.H. (1976). Cysteinyl flavin in monoamine oxidase from the central nervous system. Ciba Foundation Symposium No. 39 pp 4957, Amsterdam: Elsevier.
  • SIMPSON, L.L. (1978). Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine. Biochem. Pharmacol., 27, 15911595.
  • SPEISER, Z., LEVY, R. & COHEN, S. (1998). Effect of N-propargyl-1R-aminoindan (rasagiline) in models of motor and cognition disorders. J. Neural Transm., Suppl., 52, 287300.
  • SQUIRES, R.F. (1972). Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability. Adv. Biochem. Psychopharmacol., 5, 355370.
  • STERLING, J., VEINBERG, A., LERNER, D., GOLDENBERG, W., LEVY, R., YOUDIM, M.B.H. & FINBERG, J.P.M. (1998). (R)(+)-N-Propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J. Neural. Transm., 52(Suppl). 301305.
  • TIPTON, K.F. & YOUDIM, M.B.H. (1983). The assay of monoamine oxidase activity. In: Methods in Biogenic Amine Research.Parvez, S. Nagatsu, T., Nagatsu, I. & Parvez, H. (eds). pp. 441467, Amsterdam: Elsevier.
  • YOUDIM, M.B.H. (1978). The active centers of monoamine oxidase types A and B; binding with 14C-clorgyline and 14C-deprenyl. J. Neural. Transm., 43, 199208.
  • YOUDIM, M.B.H., FINBERG, J.P.M., LEVY, R., STERLING, J., LERNER, D., BERGER-PASKIN, T. & YELLIN, H. (1995). R-Enantiomers of N-propargyl-amino indian compounds. Their preparation and pharmaceuticals containing them. U.S. patent., 5, 457, 133.
  • YOUDIM, M.B.H. & TATTON, W.G. (1999). Nueroprotective properties of anti-Parkinson drug rasagiline and its optical isomer. Neurosci. Lett., In press.